ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for In Vivo Delivery Therapies

 ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for In Vivo Delivery Therapies

ProBioGen and CRISPR Therapeutics Signs a Multi-Year Research Collaboration for In Vivo Delivery Therapies

Shots:

  • The companies collaborated to develop and commercialize novel in vivo delivery of CRISPR/Cas9 using ProBioGen’s technology. CRISPR Therapeutics also holds an option to license the developed product
  • The focus of the agreement is to expand CRISPR Therapeutics’ in vivo delivery technology in fields of hemoglobinopathies, oncology, regenerative medicine and rare diseases
  • CRISPR Therapeutics’ CRISPR/Cas9 is a gene editing technology used to modify, delete or correct regions in DNA

Click here to read full press release/ article | Ref: CRISPR Therapeutics| Image: Contract Pharma 

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post